PSEUDOVITELLIFORM MACULOPATHY SECONDARY TO BRAF AND MEK INHIBITORS IN A PATIENT WITH METASTASIC MELANOMA

被引：0
|
作者：
Alba-Linero, C. [1 ]
Rocha De Lossada, C. [1 ]
Delgado-Fernandez, A. S. [1 ]
Jodar-Marquez, M. [1 ]
Calvo De Mora, M. Rodriguez [1 ]
Berciano-Guerrero, M. A. [2 ]
机构：
[1] Hosp Reg Malaga, Plaza Hosp Civil, Ophthalmol Dept, Malaga 29009, Spain
[2] Hosp Reg Malaga, Oncol Dept, Malaga, Spain
来源：
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS | 2019年 / 33卷 / 05期
关键词：
neuroepithelial detachment; metastasic melanoma; BRAF inhibitors; MEK inhibitors; pseudovitelliform;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1497 / 1500
页数：4
相关论文
共 50 条
  • [1] Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma
    F. Consoli
    M. Bersanelli
    G. Perego
    S. Grisanti
    B. Merelli
    A. Berruti
    F. Petrelli
    Clinical and Translational Oncology, 2020, 22 : 900 - 907
  • [2] Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma
    Consoli, F.
    Bersanelli, M.
    Perego, G.
    Grisanti, S.
    Merelli, B.
    Berruti, A.
    Petrelli, F.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (06) : 900 - 907
  • [3] Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
    Eroglu, Zeynep
    Ribas, Antoni
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (01) : 48 - 56
  • [4] Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma
    Fauviaux, E.
    Promelle, V
    Boucenna, V
    Jany, B.
    Errera, M. H.
    Delbarre, M.
    Boucenna, W.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2022, 45 (06): : 612 - 618
  • [5] Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
    Carlino, Matteo S.
    Todd, Jason R.
    Gowrishankar, Kavitha
    Mijatov, Branka
    Pupo, Gulietta M.
    Fung, Carina
    Snoyman, Stephanie
    Hersey, Peter
    Long, Georgina V.
    Kefford, Richard F.
    Rizos, Helen
    MOLECULAR ONCOLOGY, 2014, 8 (03) : 544 - 554
  • [6] Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review
    Basilicata, Michele
    Terrano, Vincenzo
    D'Aurelio, Alessandro
    Bruno, Giovanni
    Troiani, Teresa
    Bollero, Patrizio
    Napolitano, Stefania
    HEALTHCARE, 2024, 12 (01)
  • [7] BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
    Garutti, Mattia
    Bergnach, Melissa
    Polesel, Jerry
    Palmero, Lorenza
    Pizzichetta, Maria Antonietta
    Puglisi, Fabio
    CANCERS, 2023, 15 (01)
  • [8] Impact of BRAF and MEK Inhibitors on Gingival Hyperplasia in Melanoma Patients-A Case Report
    Veljovic, Tanja
    Djuric, Milanko
    Gusic, Ivana
    Vuckovic, Nada
    Ramic, Bojana
    Mirnic, Jelena
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (01)
  • [9] The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
    Mezi, Silvia
    Botticelli, Andrea
    Scagnoli, Simone
    Pomati, Giulia
    Fiscon, Giulia
    De Galitiis, Federica
    Di Pietro, Francesca Romana
    Verkhovskaia, Sofia
    Amirhassankhani, Sasan
    Pisegna, Simona
    Gentile, Giovanna
    Simmaco, Maurizio
    Gohlke, Bjoern
    Preissner, Robert
    Marchetti, Paolo
    CANCERS, 2023, 15 (18)
  • [10] Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors
    Bafaloukos, Dimitrios
    Papaxoinis, George
    Linardou, Helena
    Diamantopoulos, Panagiotis
    Laskarakis, Apostolos
    Anastasopoulou, Amalia
    Sergentanis, Theodoros N.
    Tarampikou, Anthi
    Tsoutsos, Dimosthenis
    Gogas, Helen
    MELANOMA RESEARCH, 2019, 29 (04) : 428 - 434
12345